ClinicalTrials.gg
Status unknownNCT05863832CIPRO-001Updated May 18, 2023

Study to Assess the Safety & Efficacy of Oral Ciprodiazole Versus Currently Used Ciprofloxacin & Metronidazole

A Phase 4 interventional study of Ciprodiazole and Ciprofloxacin Tablets & Metronidazole tablets in Surgical Site Infections, sponsored by MinaPharm Pharmaceuticals. Status unknown at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-05-18.

Sponsored by MinaPharm Pharmaceuticals · Phase 4, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Apr 2023), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Aug 2021, registered Apr 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Surgical Wound Infection with a site in Egypt — 8 open to participants now, 10 under way, 1 of them phase 3. Surgical Wound Infection · Egypt.

Planned enrollment
8th of 23
312 · median 200
Started
2021
with 1 other
Phase 4
7 of 27
3 open now
Registered
9th of 27
by date

Among the 27 studies in Surgical Wound Infection with a site in Egypt, this one is the 8th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2021, is one of 7 in phase 4, and was the 9th registered.

Surgical Wound Infection

747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.

Browse Surgical Wound Infection studies →

Open to participants now

8 of the 27 studies in Surgical Wound Infection with a site in Egypt are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 85 Surgical Wound Infection studies recruiting now, 62 (73%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Surgical Wound Infection with a site in Egypt, or all of them as a file.
02

Study summary

This study aims to assess the safety \& efficacy of Oral Ciprodiazole® versus currently used Ciprofloxacin Tablets \& Metronidazole tablets in pelvi-abdominal infections and following IV antibiotics in post-operative period, for pelvi-abdominal surgeries or acute conditions

Read the detailed description

Primary Objective

  1. Primary Safety:

    To compare safety of oral Ciprodiazole ® tablets (Ciprofloxacin/Metronidazole) versus currently used Ciprofloxacin Tablets \& Metronidazole tablets for pelvi-abdominal infections, either non-operative or post-operative following IV antibiotics.

  2. Primary Efficacy:

To compare efficacy of oral Ciprodiazole ® tablets (Ciprofolxacin/Metronidazole) versus currently used Ciprofloxacin Tablets \& Metronidazole tablets for pelvi-abdominal infections, either non-operative or post-operative following IV antibiotics.

Secondary Objective

  1. Secondary Safety:

    • Presence of any signs/symptoms of post-operative wound infection such as redness, fever or wound discharge.
    • Presence of undesirable effects on total leukocyte count and liver enzymes (SGOT\& SGPT)
  2. Secondary Efficacy:

    • To compare the complete resolution or improvement of Pelvi-abdominal infection between ciprodiazole® versus combined treatment, based on pelvi-abdominal ultrasound and others
    • To compare the days for complete healing of post-operative wounds between ciprodiazole® versus combined treatment

STUDY DURATION:

  • Subjects will be enrolled for 12 months including screening visit
  • Follow up for 15 days from enrolment

STUDY POPULATION:

312 Egyptian Patients with pelvi-abdominal infection or started IV antibiotics in post-operative period, for pelvi - abdominal surgeries and/or acute conditions

ASSESSMENT SCHEDULE:

Subjects will be enrolled for 12 months including screening visit

  • Visit 1: Screening and treatment initiation visit, Day 0
  • Follow-up 1 visit: Day 8 (+/-) 3 days
  • Follow-up 2 visit \& End of study visit: Day 15 (+/-) 3 days
03

Conditions studied

  • Surgical Site Infections
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Egyptian male and female patients aged between 18-65 years' old
  2. Subjects having pelvi-abdominal infections such as and not limited to: Ulcerative Colitis, Diverticulitis, Cholecystitis and Pelvic Inflammatory Diseases (PID), as oophoritis and salpingo-oophoritis.
  3. Subjects during post-operative period for pelvi-abdominal surgery and following IV medication with Metronidazole injection plus third generation cephalosporin.
  4. Subjects who are willing to sign Form (ICF) and ready to comply with the protocol for the duration of the study

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a history of to any of the active ingredients of the treatments used
  2. Subjects who are receiving or received any other antibiotics during the previous two weeks, rather than IV treatment in the first post-operative 48 hours, mentioned in the protocol
  3. Subjects with Pelvi-abdominal infection and performed surgery after failure of oral antibiotics.
  4. Subjects having surgeries such as colorectal surgeries.
  5. Subjects with any medical condition requiring the usage of the following medications:

    • Drugs that induce microsomal liver enzymes, such as Phenytoin or Phenobarbital.
    • Drugs that decrease microsomal liver enzymes activity, such as cetrimide.
    • Theophylline
    • Antacids containing magnesium and aluminum, supplements and other products containing calcium, iron or zinc
    • Tizanidine
  6. Subjects with uncontrolled diabetes mellitus; FBG > 200 mg/ml
  7. All subjects with renal impairment (S. Creatinine > 1.5 mg/dL)
  8. All subjects with hepatic impairment ( Score B-C)
  9. Subjects with liver enzymes ( \& SGPT > 2 Normal range)
  10. Pregnant or breast-feeding women
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
312 participants (estimated)

Study arms

  • Experimental
    Ciprodiazole

    Ciprodiazole Tablets: (Ciprofloxacin 500 mg \& Metronidazole 500 mg), 1 tablet every 12 hours up to 15 days

    Drug: Ciprodiazole

  • Active comparator
    Ciprofloxacin 500 mg Tablets & Metronidazole 500 mg tablets

    Ciprofloxacin 500 mg Tablets: 1 tablet every 12 hours up to 15 days Metronidazole 500 mg tablets: 1 tablet every 8 hours up to 10 days

    Drug: Ciprofloxacin Tablets & Metronidazole tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    Incidence of serious/ non-serious adverse events

    Time frame: Up to 15 Days

  2. Wounds healing

    Complete healing of the of post-operative wounds

    Time frame: Up to 15 Days

  3. Resolution of pelvi-abdominal infection

    Complete resolution for pelvi-abdominal infection, based on clinical response and/or pelvi-abdominal ultrasound and others

    Time frame: Up to 15 Days

Secondary outcomes

  1. Signs of post-operative wound infection

    Presence of any signs of post-operative wound infection such as redness, fever or wound discharge

    Time frame: Up to 15 Days

  2. Change in Safety Lab measures

    Change in Total Leukocyte count and serum Liver enzymes (SGOT, SGPT) between baseline (visit 1) to End of study visit (Follow up 2 V)

    Time frame: Up to 15 Days

  3. Infection outcome

    Complete resolution, improvement, failure or relapse of pelvi-abdominal infection, based on pelvi-abdominal ultrasound and/or clinical response

    Time frame: Up to 15 Days

  4. Healing Days

    Days for complete healing of post-operative wounds between the 2 groups

    Time frame: Up to 15 Days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2021 (actual). Primary completion is estimated for Dec 2023, 28 months after the start.

Of 47 phase 4 interventional studies under Surgical Wound Infection, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 51. This study's planned 28 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2023
First posted
May 18, 2023
StartActual
Aug 17, 2021
Primary completionEst.
Dec 31, 2023
CompletionEst.
Dec 31, 2023
Last update
May 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05863832
Lead sponsor
MinaPharm Pharmaceuticals
Responsible party
Sponsor
First posted
May 18, 2023
Start date
Aug 17, 2021
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
May 18, 2023

Study contacts

Ahmed Dr El Kased, PhD
Contact
elkased@outlook.com
+20 100 663 9418
Abdelaziz Dr Sakr, MBBCH
Contact
abdelaziz.ragab@med.menofia.edu.eg
+20 109 009 0254
Ahmed Dr El Kased, PhD
principal investigator · Faculty of Medicine - Menoufia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion